All News

From the story of HGTV’s “Love it or List it” co-host Hilary Farr’s cancer journey to “Pistol Annies” singer Ashley Monroe ringing the bell after finishing cancer treatment, here’s what’s happening in the cancer landscape this week.

CURE® took a look back at our most-read lung cancer stories from this year.

City of Hope has opened its first-in-human clinical trial for an investigational therapy in patients with advanced breast cancer.

The drug Venclexta may address an unmet need for patients with Waldenström macroglobulinemia via a non-chemotherapeutic, safe and effective treatment option.

The vaccine, which protects patients from seven different strains related to HPV-related cancers, may be considered part of routine oncology care for survivors.

A caregiver writes a poem expressing joy over her daughter’s clean scan results after having had breast cancer in her own version of the 12 Days of Christmas.

On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.

Although the recent FDA approval of Keytruda was exciting for high-risk, nonmetastatic renal cell carcinoma, an expert from The University of MD Anderson Cancer Center notes more work is needed, particularly when it comes to individualizing treatment.

Here’s a look back at CURE®’s top-performing melanoma content from the year 2021.

A man who has spent five years dealing with cancer shares his thoughts on the COVID-19 booster shot.

Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma.

The addition of a drug commonly used to treat arthritis may reduce the risk of graft-versus-host-disease in patients who underwent haploidentical allogeneic stem cell transplant.

Calquence, a next-generation BTK inhibitor, significantly prolonged survival compared with standard of care, along with no new side effects at three years in chronic lymphocytic leukemia. These findings also pertained to some patients with high-risk genetic features.

A pancreatic cancer survivor explains the anguish he felt over seeing a young mother and her child in the waiting room for his oncologist, and what words of advice he would offer her.

Dr. Don S. Dizon discusses how cancer centers can be more inclusive to the LGBTQ+ community, from the naming of the institutions to the types of magazines found in the waiting rooms.

The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.

The use of a novel drug combination yielded positive outcomes in patients with B-cell lymphomas for whom CAR-T cell therapy or stem cell transplant isn’t an option.

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

A cancer survivor explains how his holiday traditions changed after his wife was sick with and eventually died from cancer, and why each changing tradition holds a special place in his heart.

For patients with neuroendocrine tumors that have spread, curating a liver-directed approach may make their treatment process less risky and less invasive, according to an expert.

Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.

The immunotherapy Kymriah offered similar benefits in patients younger than and older than 18 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.

Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.

A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.

In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.